Mammalian Target of Rapamycin (mTor) Mediates Tau Protein Dyshomeostasis
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Previous evidence from post-mortem Alzheimer disease (AD) brains and drug (especially rapamycin)-oriented in vitro and in vivo models implicated an aberrant accumulation of the mammalian target of rapamycin (mTor) in tangle-bearing neurons in AD brains and its role in the formation of abnormally hyperphosphorylated tau. Compelling evidence indicated that the sequential molecular events such as the synthesis and phosphorylation of tau can be regulated through p70 S6 kinase, the well characterized immediate downstream target of mTor. In the present study, we further identified that the active form of mTor per se accumulates in tangle-bearing neurons, particularly those at early stages in AD brains. By using mass spectrometry and Western blotting, we identified three phosphoepitopes of tau directly phosphorylated by mTor. We have developed a variety of stable cell lines with genetic modification of mTor activity using SH-SY5Y neuroblastoma cells as background. In these cellular systems, we not only confirmed the tau phosphorylation sites found in vitro but also found that mTor mediates the synthesis and aggregation of tau, resulting in compromised microtubule stability. Changes of mTor activity cause fluctuation of the level of a battery of tau kinases such as protein kinase A, v-Akt murine thymoma viral oncogene homolog-1, glycogen synthase kinase 3β, cyclin-dependent kinase 5, and tau protein phosphatase 2A. These results implicate mTor in promoting an imbalance of tau homeostasis, a condition required for neurons to maintain physiological function. Background: Perturbations of the mammalian target of rapamycin (mTor) signaling pathway are implicated in Alzheimer disease (AD). Results: The activated mTor alters the activity of major tau kinases contributing to the formation of tau dyshomeostasis. Conclusion: We established a cellular system using genetic activation of mTor that developed authentic AD-like changes. Significance: The study provides potential tools for identifying tau-based therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 2×
“Its phosphorylation at Ser-2448 by Akt activates mTor, whereas phosphorylation at the Thr-2446 site by 5 -adenosinemonophosphate-activated protein kinase inactivates mTor (23, 58).”
BackgroundReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“Although associations per se cannot prove cause-effect relationships, the formation of tau inclusions (NFTs) is widely thought to contribute to AD pathogenesis as NFT formation correlates with the duration and progression of AD (4).”
BackgroundMolecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Tau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807
Cited by
mTOR substrate phosphorylation in growth control
Battaglioni, S., Benjamin, D., Wälchli, M., Maier, T., & Hall, M. N. (2022) · Cell · doi:10.1016/j.cell.2022.04.013 · Cited by 434
mTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 356
Piras, A., Collin, L., Grüninger, F., Graff, C., & Rönnbäck, A. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0292-9 · Cited by 271
Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment
Abcouwer, S. F., & Gardner, T. W. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12412 · Cited by 254
Obesity as a Risk Factor for Dementia and Alzheimer’s Disease: The Role of Leptin
Flores-Cordero, J. A., Pérez-Pérez, A., Jiménez-Cortegana, C., Alba, G., Flores-Barragán, A., & Sánchez-Margalet, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095202 · Cited by 212
mTor mediates tau localization and secretion: implication for Alzheimer’s disease
Tang, Z., Ioja, E., Bereczki, E., Hultenby, K., Li, C., Guan, Z., Winblad, B., & Pei, J.-J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.03.003 · Cited by 112
Self-citationGentry, E. G., Henderson, B. W., Arrant, A. E., Gearing, M., Feng, Y., Riddle, N. C., & Herskowitz, J. H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2336-15.2016 · Cited by 90
Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies.
Tramutola, A., Lanzillotta, C., & Di Domenico, F. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1244482 · Cited by 69
Yang, Y., & Zhang, L. (2020) · Food & Function · doi:10.1039/c9fo02611h · Cited by 57
Wu, J., Zhou, S.-L., Pi, L.-H., Shi, X.-J., Ma, L.-R., Chen, Z., Qu, M.-L., Li, X., Nie, S.-D., Liao, D.-F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17257 · Cited by 50
Self-citationFolch, J., Patraca, I., Martínez, N., Pedrós, I., Petrov, D., Ettcheto, M., Abad, S., Marin, M., Beas-Zarate, C., & Camins, A. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.05.002 · Cited by 48
Tang, Z., Lai, C., Luo, J., Ding, Y., Chen, Q., & Guan, Z. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22705 · Cited by 26
Self-citationRetromer dysfunction at the nexus of tauopathies
Carosi, J. M., Denton, D., Kumar, S., & Sargeant, T. J. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00727-2 · Cited by 16
Sills, A. M., Artavia, J. M., DeRosa, B. D., Ross, C. N., & Salmon, A. B. (2019) · American Journal of Primatology · doi:10.1002/ajp.22927 · Cited by 17
Gąssowska-Dobrowolska, M., Czapski, G. A., Cieślik, M., Zajdel, K., Frontczak-Baniewicz, M., Babiec, L., & Adamczyk, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087303 · Cited by 10
“The active form of mTOR aberrantly accumulates in NFT-bearing neurons and mediates Tau phosphorylation in AD-related epitopes in vitro, as well as synthesis and aggregation of Tau, resulting in compromised MTs stability [54,55].”
Background
Metadata
- Authors
- Tang, Z., Bereczki, E., Zhang, H., Wang, S., Li, C., Ji, X., Branca, R. M., Lehtiö, J., Guan, Z., Filipcik, P., Xu, S., Winblad, B., & Pei, J.-J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 288
- Issue
- 22
- Pages
- 15556-15570
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2059124041
- Cited by
- 124
- References
- 25
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.